试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-10
Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury
编号:NCT02237547登记状态:入组前撤回企业 / 申办者:Translational Biosciences
药物 / 成分:Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells
登记的停止原因(原文):No enrollment.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-10
Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis
编号:NCT02237846登记状态:入组前撤回企业 / 申办者:Translational Biosciences
药物 / 成分:Human umbilical cord tissue-derived mesenchymal stem cells
登记的停止原因(原文):No enrollment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-10
A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet
编号:NCT03156127登记状态:入组前撤回企业 / 申办者:Boryung Pharmaceutical Co., Ltd
药物 / 成分:BR-UPS 5 mg tablet, Inisia 5 mg tablet
登记的停止原因(原文):Problem of Investigational Products
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-09
A Comparison of Exparel Local Anesthetic in Total Knee Arthroplasty (TKA) Patients
编号:NCT02765815登记状态:入组前撤回企业 / 申办者:Holy Cross Hospital, Florida
药物 / 成分:Liposomal bupivacaine, 266mg、Bupivacaine 0.5 % with Epinephrine、Ketorolac 30mg、Morphine 10mg
登记的停止原因(原文):competing protocol
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-09
CPC-201 Alzheimer's Disease Type Dementia: PET Study
编号:NCT02860065登记状态:入组前撤回企业 / 申办者:Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
药物 / 成分:CPC-201、Positron emission tomography (PET)
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-07
Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients
编号:NCT01612299登记状态:入组前撤回企业 / 申办者:University of Kentucky
药物 / 成分:Zortress® /Everolimus
登记的停止原因(原文):Funding was withdrawn for this study by the sponsor.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-07
DAA in the Risk of Recurrence After Curative Treatment of HCC
编号:NCT02959359登记状态:入组前撤回企业 / 申办者:Taipei Veterans General Hospital, Taiwan
药物 / 成分:Ledipasvir 90mg/Sofosbuvir 400 mg、Ribavirin
登记的停止原因(原文):The supplies of study drug were halted by Gilead Sciences Ltd.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-02
Brain Imaging: Cocaine Effects & Medication Development - 5
编号:NCT00000270登记状态:入组前撤回企业 / 申办者:New York State Psychiatric Institute
药物 / 成分:Cocaine
登记的停止原因(原文):Study never opened; never enrolled participants
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-02
EEG Studies of IV Methylphenidate-Induced Emergence From Anesthesia
编号:NCT02429076登记状态:入组前撤回企业 / 申办者:Massachusetts General Hospital
药物 / 成分:IV methylphenidate、Placebo、Sevoflurane、Propofol
登记的停止原因(原文):We are not going to complete this study with healthy volunteers at this time.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-01
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
编号:NCT00386516登记状态:入组前撤回企业 / 申办者:Galectin Therapeutics Inc.
药物 / 成分:GM-CT-01、5-Fluorouracil
登记的停止原因(原文):Financing and re-organization
查看官方原始记录 ↗